Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Denis ChoquetteLouis BessetteEvo AlemaoBoulos HaraouiRoelien PostemaJean-Pierre RaynauldLouis CoupalPublished in: Arthritis research & therapy (2019)
Abatacept and TNFi use demonstrated similar persistence rates at 9 years as a first-line biologic agent. As a second-line biologic agent, abatacept had better persistence rates over a TNFi.